RE-BVS – Piemonte Repository

Sfoglia per AUTORE
ASSOULINE S
Collezione AOU Città della Salute di Torino

Items : 3

Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study. in American journal of hematology / Am J Hematol. 2023 Nov;98(11):1762-1771. doi: 10.1002/ajh.27073. Epub 2023 Aug 30.

2023
AOU Città della Salute di Torino

Druker BJ; Piazza R; Stagno F; Saussele S; Maffioli M; Caocci G; Galimberti S; le Coutre P; Lunghi F; Cerrano M; Capodanno I; Iurlo A; Bucelli C; Triguero A; Alvarez-Larran A; Elena C; Miggiano MC; Abruzzese E; Pungolino E; Busque L; Assouline S; Nicolini FE; Zambrotta GPM; Fava C; Guglielmana V; Colombo F; Antolini L; Gambacorti-Passerini C;

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. in Leukemia & lymphoma / Leuk Lymphoma. 2018 Dec;59(12):2904-2910. doi: 10.1080/10428194.2018.1452208. Epub 2018 Apr 4.

2018
AOU Città della Salute di Torino

Mann KK; Assouline S; Perali G; Volpetti S; Cavallo F; Lenti V; Piccaluga PP; Pileri SA; Patti C; Tucci A; Califano C; Zinzani PL; Vitolo U; Chiappella A; Ladetto M; Zanni M; Gaidano G; Angelucci E; Ciccone G; Evangelista A; Sabattini E; Rossi M; Salvi F; Zaja F; Morin R; Alcaide M; Bushell K; Fanin R; Levis A; et alii...

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2017 Sep 1;28(9):2169-2178. doi: 10.1093/annonc/mdx289.

2017
AOU Città della Salute di Torino

Dreyling M; Morschhauser F; Bouabdallah K; Bron D; Cunningham D; Assouline SE; Verhoef G; Linton K; Thieblemont C; Vitolo U; Hiemeyer F; Giurescu M; Garcia-Vargas J; Gorbatchevsky I; Liu L; Koechert K; Peña C; Neves M; Childs BH; Zinzani PL;